Sensors 2009, 9(8), 6471-6503; doi:10.3390/s90806471
Review

Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity

1 Unit of General Pathology and Immunology, Department of Biomedical Sciences and Biotechnology, School of Medicine, University of Brescia, Brescia, 25123, Italy 2 Chemistry for Technologies Laboratory and Department of Mechanical and Industrial Engineering, School of Engineering, University of Brescia, Brescia, 25123, Italy
* Author to whom correspondence should be addressed.
Received: 24 July 2009; in revised form: 17 August 2009 / Accepted: 19 August 2009 / Published: 20 August 2009
(This article belongs to the Special Issue State-of-the-Art Sensors Technology in Italy)
PDF Full-text Download PDF Full-Text [780 KB, uploaded 19 August 2009 21:51 CEST]
Abstract: Angiogenesis, the process of new blood vessel formation, is implicated in various physiological/pathological conditions, including embryonic development, inflammation and tumor growth. Fibroblast growth factor-2 (FGF2) is a heparin-binding angiogenic growth factor involved in various physiopathological processes, including tumor neovascularization. Accordingly, FGF2 is considered a target for antiangiogenic therapies. Thus, numerous natural/synthetic compounds have been tested for their capacity to bind and sequester FGF2 in the extracellular environment preventing its interaction with cellular receptors. We have exploited surface plasmon resonance (SPR) technique in search for antiangiogenic FGF2 binders/antagonists. In this review we will summarize our experience in SPR-based angiogenesis research, with the aim to validate SPR as a first line screening for the identification of antiangiogenic compounds.
Keywords: angiogenesis; fibroblast growth factor-2; heparan-sulfate proteoglycans; heparin; interactions; pentraxin 3; peptides; surface plasmon resonance; thrombospondin-1

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Rusnati, M.; Bugatti, A.; Mitola, S.; Leali, D.; Bergese, P.; Depero, L.E.; Presta, M. Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity. Sensors 2009, 9, 6471-6503.

AMA Style

Rusnati M, Bugatti A, Mitola S, Leali D, Bergese P, Depero LE, Presta M. Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity. Sensors. 2009; 9(8):6471-6503.

Chicago/Turabian Style

Rusnati, Marco; Bugatti, Antonella; Mitola, Stefania; Leali, Daria; Bergese, Paolo; Depero, Laura E.; Presta, Marco. 2009. "Exploiting Surface Plasmon Resonance (SPR) Technology for the Identification of Fibroblast Growth Factor-2 (FGF2) Antagonists Endowed with Antiangiogenic Activity." Sensors 9, no. 8: 6471-6503.

Sensors EISSN 1424-8220 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert